Kepler-86

Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, August 11, 2022

DALLAS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Vaxxinity expects to complete an end-of-treatment analysis of Part B in the second half of 2022.
  • Phase 1 Part A trial of UB-312 in healthy volunteers results published in Movement Disorders, April 15, 2022 .
  • Subsequent to the quarter-end, Vaxxinity began enrolling healthy volunteers into a Phase 1 clinical trial evaluating UB-313 for safety, tolerability, and immunogenicity.
  • Vaxxinity expects a topline readout in the second half of 2022, and if successful, these data will support global marketing authorization applications.

Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT

Retrieved on: 
Wednesday, March 16, 2022

Mr. Luci will be presenting during the Fireside Chat with Acurx Pharmaceuticals, Inc. at 9:30 am ET on Monday, March 28, 2022.

Key Points: 
  • Mr. Luci will be presenting during the Fireside Chat with Acurx Pharmaceuticals, Inc. at 9:30 am ET on Monday, March 28, 2022.
  • The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.
  • About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

Retrieved on: 
Monday, March 7, 2022

David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

Key Points: 
  • David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
    About the Ibezapolstat Phase 2 Clinical Trial.
  • In this cohort, 10 patients with diarrhea caused by C. difficile were treated with ibezapolstat 450 mg orally, twice daily for 10 days.
  • About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections.
  • However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Nanoscope Therapeutics CEO Sulagna Bhattacharya Elected to BIO Emerging Companies Section Governing Board

Retrieved on: 
Thursday, February 17, 2022

DALLAS, Feb. 17, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a late clinical-stage ocular gene therapy company, today announced the election of CEO Sulagna Bhattacharya to the Biotechnology Innovation Organization (BIO) Emerging Companies Section Governing Board .

Key Points: 
  • DALLAS, Feb. 17, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc. , a late clinical-stage ocular gene therapy company, today announced the election of CEO Sulagna Bhattacharya to the Biotechnology Innovation Organization (BIO) Emerging Companies Section Governing Board .
  • Washington D.C.-based BIO is the world's largest Biotechnology advocacy organization representing companies, academic institutions, and local biotechnology centers across the U.S. and globally.
  • "We are very pleased to have Sulagna join our board," said Dr. Michelle McMurry-Heath, President & CEO of BIO.
  • BIO also produces the BIO International Convention ,the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings globally.

Vera Therapeutics Presents Phase 2a Data Showing Atacicept Reduces Serum Gd-IgA1 in Patients with IgA Nephropathy at the American Society of Nephrology Kidney Week 2021

Retrieved on: 
Thursday, November 4, 2021

In the Phase 2a randomized, placebo-controlled JANUS trial in 16 IgAN patients, serum galactose-deficient IgA1 (Gd-IgA1) was assessed at baseline, weeks 4, 12, 24, 48, and 72.

Key Points: 
  • In the Phase 2a randomized, placebo-controlled JANUS trial in 16 IgAN patients, serum galactose-deficient IgA1 (Gd-IgA1) was assessed at baseline, weeks 4, 12, 24, 48, and 72.
  • Results showed that atacicept, administered subcutaneously once weekly, demonstrated a substantial reduction in serum Gd-IgA1 in a dose-dependent manner that was durable through 72 weeks.
  • The presentation titled, Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients, was included in the session entitled, Glomerular Disease: Treatment and Outcomes (PO1203-3).
  • The Phase 2a JANUS trial was the first study to show substantial Gd-IgA1 reduction with atacicept in IgAN patients, said Professor Barratt.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Retrieved on: 
Monday, September 13, 2021

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Retrieved on: 
Monday, September 13, 2021

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria

Retrieved on: 
Thursday, August 5, 2021

Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p

Key Points: 
  • Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p
  • Uox reductions were significant in participants with PH1 while participants with PH2 (5 nedosiran and 1 placebo) showed inconsistent results in this trial.
  • We expect the results from the PHYOX2 trial to support marketing authorization applications in the U.S. and other major markets.
  • PHYOX2 is part of the broader PHYOX clinical trial program designed to evaluate nedosiran in participants with PH1, PH2 and PH3.

Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

Retrieved on: 
Friday, June 21, 2019

Investigators reported additional results evaluating DCR-PHXC in patients with primary hyperoxaluria type 1 (PH1) and type 2 (PH2), building on previously disclosed data showing substantial reductions in 24-hour urinary oxalate levels following a single-dose of DCR-PHXC.

Key Points: 
  • Investigators reported additional results evaluating DCR-PHXC in patients with primary hyperoxaluria type 1 (PH1) and type 2 (PH2), building on previously disclosed data showing substantial reductions in 24-hour urinary oxalate levels following a single-dose of DCR-PHXC.
  • The results will be presented at the Oxalosis & Hyperoxaluria Foundation (OHF) International Hyperoxaluria Workshop in Boston on June 22.
  • The latest data from PHYOX1 provide more information on the effects of DCR-PHXC in individuals with PH1 as well as individuals with PH2.
  • Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort.

Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)

Retrieved on: 
Friday, March 29, 2019

The data showed post-dose reductions in 24-hour urinary oxalate levels in adult and adolescent study participants with primary hyperoxaluria type 1 (PH1) and type 2 (PH2).

Key Points: 
  • The data showed post-dose reductions in 24-hour urinary oxalate levels in adult and adolescent study participants with primary hyperoxaluria type 1 (PH1) and type 2 (PH2).
  • The data were presented in a poster on March 28 at the German Society of Pediatric Nephrology 50th Annual Meeting in Cologne, Germany.
  • Studies have shown that people who are completely deficient in LDHA show no liver dysfunction and can lead normal lives.
  • Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.